Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group
暂无分享,去创建一个
A. Jemal | J. Ferlay | J. Lortet-Tieulent | F. Bray | S. Devesa | M. Cook | D. Check | M. Laversanne | C. Zhou
[1] Pamela A. Shaw,et al. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. , 2002, Urology.
[2] N. Lawrentschuk,et al. Population‐based analysis of prostate‐specific antigen (PSA) screening in younger men (<55 years) in Australia , 2014, BJU international.
[3] B A Miller,et al. The role of increasing detection in the rising incidence of prostate cancer. , 1995, JAMA.
[4] E. Feuer,et al. Permutation tests for joinpoint regression with applications to cancer rates. , 2000, Statistics in medicine.
[5] Peter H Gann,et al. Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.
[6] Wadih Arap,et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.
[7] S Kamen,et al. The task force. , 1976, Journal of hospital dental practice.
[8] K. Cooney,et al. Prostate cancer in young men: an important clinical entity , 2014, Nature Reviews Urology.
[9] S. Taneja,et al. Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. , 2009, Reviews in urology.
[10] Lisa M. Schwartz,et al. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? , 2003, JAMA.
[11] J. Blandy. Geoffrey Duncan Chisholm , 1997 .
[12] David C. Miller,et al. Prostate Cancer Registries: Current Status and Future Directions. , 2016, European urology.
[13] F. Bray,et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. , 2007, Journal of the National Cancer Institute.
[14] Jacques Ferlay,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .
[15] E. Feuer,et al. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 1999, Journal of the National Cancer Institute.
[16] L. Kessler,et al. Rise in prostatic cancer incidence associated with increased use of transurethral resection. , 1990, Journal of the National Cancer Institute.
[17] Jacques Ferlay,et al. Cancer in Africa 2012 , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[18] F. Hamdy,et al. Prostate‐specific antigen testing rates remain low in UK general practice: a cross‐sectional study in six English cities , 2011, BJU international.
[19] P. Stattin,et al. Re: Giorgio Gandaglia, Freddie Bray, Matthew R. Cooperberg, et al. Prostate Cancer Registries: Current Status and Future Directions. Eur Urol 2015;68:e110. , 2015, European urology.
[20] S. Eggener,et al. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Schwartz,et al. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. , 1999, The Journal of urology.
[22] S. Naito,et al. Japanese Urological Association guidelines on prostate‐specific antigen‐based screening for prostate cancer and the ongoing cluster cohort study in Japan , 2008, International journal of urology : official journal of the Japanese Urological Association.
[23] E. Schernhammer,et al. Prostate cancer and prostate-specific antigen (PSA) screening in Austria , 2005, Wiener klinische Wochenschrift.
[24] Patrick C. Walsh,et al. American Cancer Society Guidelines for the Early Detection of Cancer , 2002, CA: a cancer journal for clinicians.
[25] M. Barry,et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. , 1993, JAMA.
[26] Douglas K Owens,et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.
[27] V. Moyer,et al. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.
[28] T. Fears,et al. Graphical presentation of trends in rates. , 1995, American journal of epidemiology.
[29] Seth Falcon,et al. Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.
[30] Curtis Mettlin,et al. Defining and updating the american cancer society guidelines for the cancer‐related checkup: Prostate and endometrial cancers , 1993, CA: a cancer journal for clinicians.
[31] T. Thompson,et al. Recent trends in prostate cancer testing and incidence among men under age of 50. , 2012, Cancer epidemiology.
[32] J. Onysko,et al. Lifetime and Recent Prostate Specific Antigen (PSA) Screening of Men for Prostate Cancer in Canada , 2006, Canadian journal of public health = Revue canadienne de sante publique.
[33] Mohammad Hassan Murad,et al. Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.
[34] H. Bartsch,et al. International Agency for Research on Cancer. , 1969, WHO chronicle.
[35] J. Ferlay,et al. Prostate cancer incidence and mortality trends in 37 European countries: an overview. , 2010, European journal of cancer.
[36] H. Yasunaga,et al. Updated Japanese Urological Association Guidelines on prostate‐specific antigen‐based screening for prostate cancer in 2010 , 2010, International journal of urology : official journal of the Japanese Urological Association.
[37] J. Witjes,et al. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing. , 2013, Family practice.
[38] J. Hanley,et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.
[39] S. Moss,et al. Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. , 1997, British journal of urology.
[40] A. Jemal,et al. International variation in prostate cancer incidence and mortality rates. , 2012, European urology.
[41] Sam S. Chang,et al. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. , 2015, The Journal of urology.
[42] S. Moss,et al. Survey of the rate of PSA testing in general practice , 2001, British Journal of Cancer.
[43] T. H. van der Kwast,et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.
[44] Bey P Le. [Cancer in Africa]. , 2013, Bulletin du cancer.
[45] E. Feuer,et al. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence declinein the United States , 1998, Cancer Causes & Control.
[46] G. Smailytė,et al. Incidence of prostate cancer in Lithuania after introduction of the Early Prostate Cancer Detection Programme. , 2012, Public health.
[47] G Bartsch,et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. , 2001, Urology.
[48] S. Rosso,et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] 栗原 登,et al. Trends cancer mortality for selected sites in 24 countries , 1960 .
[50] M. Freedman,et al. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa , 2009, Infectious Agents and Cancer.
[51] Thomas Wiegel,et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.
[52] P. Walsh,et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. , 1993, The Journal of urology.